S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What to Expect from the Markets in a Recession
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What to Expect from the Markets in a Recession
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What to Expect from the Markets in a Recession
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
What to Expect from the Markets in a Recession
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:GILD

Gilead Sciences (GILD) Price Target & Analyst Ratings

$61.09
-0.82 (-1.32%)
(As of 08/5/2022 08:48 PM ET)
Add
Compare
Today's Range
$60.62
$61.84
50-Day Range
$57.72
$64.85
52-Week Range
$57.17
$74.12
Volume
6.04 million shs
Average Volume
9.09 million shs
Market Capitalization
$76.63 billion
P/E Ratio
18.63
Dividend Yield
4.78%
Price Target
$72.07

Gilead Sciences Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$72.07
17.97% Upside
High Prediction$90.00
Average Prediction$72.07
Low Prediction$56.00
TypeCurrent
8/8/21 to 8/8/22
1 Month Ago
7/9/21 to 7/9/22
3 Months Ago
5/10/21 to 5/10/22
1 Year Ago
8/8/20 to 8/8/21
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
11 Buy rating(s)
Hold
9 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$72.07$72.07$73.00$108.59
Predicted Upside17.97% Upside13.04% Upside14.46% Upside70.53% Upside
Get Gilead Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.


GILD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.21
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside17.97% Upside516.79% Upside18.64% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
2419
78.69%
Underperform Votes
655
21.31%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/15/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$63.00 ➝ $65.00+4.07%
7/12/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Brayer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$70.00+12.29%
6/7/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$63.00+1.97%
5/23/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$68.00+6.52%
5/16/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$73.00 ➝ $69.00+10.86%
4/12/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$76.00 ➝ $77.00+24.41%
3/22/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$70.00 ➝ $63.00+5.60%
3/10/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$63.00 ➝ $56.00-5.08%
2/8/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$81.00 ➝ $75.00+17.63%
2/3/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$88.00 ➝ $84.00+28.44%
2/3/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$100.00 ➝ $90.00+37.61%
2/2/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$77.00 ➝ $75.00+16.42%
2/2/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$73.00 ➝ $71.00+3.70%
1/28/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$75.00+11.49%
12/6/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$80.00+15.01%
10/31/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
5/7/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Yee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$80.00+19.49%
4/30/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
4/1/2021Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$80.00+23.78%
3/30/2021Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
2/5/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$65.00 ➝ $66.00-1.40%
1/4/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
12/22/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$75.00 ➝ $72.00+25.90%
12/16/2020Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Skorney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral$63.00 ➝ $67.00+12.74%
12/8/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
10/28/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$61.00+1.65%
9/14/2020Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Steven Seedhouse
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
8/3/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$78.00 ➝ $80.00+11.28%
7/31/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold$73.00 ➝ $74.00+5.55%
6/15/2020DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Elmar Kraus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
4/29/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell$71.00 ➝ $74.00-11.97%
4/13/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Josh Jennings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$80.00+6.27%
3/31/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$65.00-13.95%
3/2/2020HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
(Data available from 8/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Gilead Sciences Price Target - Frequently Asked Questions

What is Gilead Sciences's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Gilead Sciences stock is Hold based on the current 1 sell rating, 9 hold ratings and 4 buy ratings for GILD. The average twelve-month price prediction for Gilead Sciences is $72.07 with a high price target of $90.00 and a low price target of $56.00. Learn more on GILD's analyst rating history.

Do Wall Street analysts like Gilead Sciences more than its competitors?

Analysts like Gilead Sciences less than other Medical companies. The consensus rating for Gilead Sciences is Hold while the average consensus rating for medical companies is Buy. Learn more on how GILD compares to other companies.

Do MarketBeat users like Gilead Sciences more than its competitors?

MarketBeat users like Gilead Sciences more than other Medical companies. 78.69% of MarketBeat users gave Gilead Sciences an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Gilead Sciences's stock price have much upside?

According to analysts, Gilead Sciences's stock has a predicted upside of 13.10% based on their 12-month price targets.

What analysts cover Gilead Sciences?

Gilead Sciences has been rated by BMO Capital Markets, Cantor Fitzgerald, Morgan Stanley, Piper Sandler, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GILD) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.